Over the last 7 days, the market has remained flat, but over the past 12 months, it has risen by 20%, with earnings forecast to grow annually by 18%. In light of these conditions, investors might find value in exploring smaller or newer companies that offer potential growth opportunities. Although penny stocks are a somewhat outdated term, they still represent an investment area where companies can provide surprising value and stability.

Let's take a closer look at a couple of our picks from the screened companies.

INmune Bio (INMB)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: INmune Bio Inc. is a clinical-stage immunology company developing drugs to reprogram the innate immune system for disease treatment in the United States, with a market cap of $51.58 million.

Operations: INmune Bio Inc. has not reported any revenue segments at this time.

Market Cap: $51.58M

INmune Bio, with a market cap of US$51.58 million, is pre-revenue and debt-free, reflecting typical characteristics of a penny stock. The company has seen its share price remain highly volatile over the past three months and was recently dropped from several Russell indices but added to the Russell Microcap Value Benchmark Index. Despite its unprofitability and increased losses over five years, INmune Bio's board and management are experienced. Recent advancements include promising Phase 2 study results for XPro1595 in Alzheimer's treatment and regulatory progress for its CORDStrom platform targeting rare diseases like RDEB, potentially enhancing future growth prospects.

Identiv (INVE)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Identiv, Inc. develops, manufactures, and supplies specialty IoT products across various regions including the United States, Europe, the Middle East, and Asia-Pacific with a market cap of $70.34 million.

Operations: The company's revenue is generated from its IoT Business segment, which reported $23.63 million.

Market Cap: $70.34M

Identiv, Inc., with a market cap of US$70.34 million, is currently unprofitable but maintains a robust financial position with short-term assets exceeding liabilities and no debt. Despite its negative return on equity and high share price volatility, the company has not diluted shareholders recently and possesses a cash runway exceeding three years. Recent developments include the launch of ID-Pixels 3.0, enhancing supply chain sensing capabilities through advanced Bluetooth Low Energy technology in collaboration with Wiliot. Additionally, Identiv plans to sell its IoT business assets to Trackonomy Systems, potentially impacting future operations and revenue streams.

Vera Bradley (VRA)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Vera Bradley, Inc. designs and manufactures women's handbags, luggage and travel items, fashion and home accessories, and gifts in the United States with a market cap of $114.61 million.

Operations: The company generates revenue through its Direct segment, which contributed $229.56 million, and its Indirect segment, which added $44.14 million.

Market Cap: $114.61M

Vera Bradley, Inc., with a market cap of US$114.61 million, remains unprofitable but demonstrates financial resilience with short-term assets exceeding both short and long-term liabilities. The company has maintained its shareholder structure without significant dilution over the past year and operates debt-free. Despite ongoing losses, Vera Bradley holds a cash runway exceeding three years at current free cash flow levels. Recent strategic moves include partnering with Nordstrom to expand product availability, potentially enhancing brand visibility and customer reach. First-quarter sales rose to US$55.7 million from US$51.65 million last year, though net loss narrowed significantly to US$4.83 million from US$33.46 million previously reported.

Next Steps

• Click this link to deep-dive into the 325 companies within our US Penny Stocks screener.
• Interested In Other Possibilities? Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.